What is NDC 62225-300?

62225-300 is the product NDC for Yartemlea (narsoplimab), Narsoplimab 370 mg/2mL injection, listed with the FDA by Omeros Corporation. It has 1 package NDC, shown above in 10- and 11-digit form.

Omeros Corporation, NDC labeler code 62225. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Yartemlea?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Yartemlea NDC 62225-300 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)62225-300Labeler and product segments. Claims need a package NDC.

Product NDC at billing width62225-0300Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
62225-300-00	62225030000	1 VIAL in 1 CARTON (62225-300-00) / 2 mL in 1 VIALMarketed from Jan 20, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Yartemlea
Generic name (nonproprietary): narsoplimab
Active ingredients: Narsoplimab — 370 mg/2mL
Dosage form: Injection
Route: Intravenous
Labeler: Omeros CorporationNDC labeler code 62225
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 761152
Marketing start: Jan 20, 2026
Listing expires: Dec 31, 2027
Identifiers: Product ID 62225-300_48da2b07-9b4c-7b5f-e063-6394a90a7b62SPL ID 48da2b07-9b4c-7b5f-e063-6394a90a7b62SPL set ID f8ff990a-0d2e-433f-9615-b9b097448991RxCUI 2732298, 2732305UNII FT24ZQQ5RPUPC 0362225300007

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N462225030000 followed by a unit qualifier and the quantity

Package 62225-0300-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 20, 2026.

Indications (excerpt from the label)

YARTEMLEA is indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). YARTEMLEA is a MASP-2 inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 62225-300

What is NDC 62225-300?: 62225-300 is the product NDC for Yartemlea (narsoplimab), Narsoplimab 370 mg/2mL injection, listed with the FDA by Omeros Corporation. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Yartemlea (Narsoplimab).
What is the active ingredient?: Narsoplimab.
Who is the labeler?: Omeros Corporation, NDC labeler code 62225. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Yartemlea?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Yartemlea (Narsoplimab) NDC 62225-300